Diasurin Recorded the worst performance of the day in FTSEMib. The diagnostics company’s stock left 10.8% grounded at €158.85, after hitting an intraday low of €154. Large volumes During the entire session, approximately 872 thousand shares were traded.
DiaSorin agreed to Industrial plan for the four-year period 2022-2025 The project to redefine the institutional structure was approved. In particular, DiaSorin expects to close 2022 with a decrease in total revenue of 2%, as a result of lower sales volumes from activities related to Covid-19 (Covid sales volume decreased from 370 million euros estimated for 2021 to 150 million expected for 2022). Excluding activities related to Covid-19, DiaSorin reports revenue growth of approximately 24% for 2022. Adjusted EBITDA margin for 2022 is expected to be approximately 35%.
This writing has been prepared for informational purposes only, and may be changed at any time and cannot be construed as a solicitation of public savings. The site does not guarantee the correctness of the information and assumes no responsibility for the use of the information contained therein.
“Explorer. Devoted travel specialist. Web expert. Organizer. Social media geek. Coffee enthusiast. Extreme troublemaker. Food trailblazer. Total bacon buff.”